# US 2026/0097190 A1 · Drug delivery device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097190 A1
- Document ID: US20260097190A1
- Status: Published application
- Kind: A1
- Application number: 19/120,894
- Filed: 2023-10-16
- Published: 2026-04-09
- Earliest claimed: 2022-10-14
- Assignees: Liberum Health Ltd
- Applicants: Liberum Health Ltd
- Inventors: Alexander SEIFALIAN; Amelia SEIFALIAN; Chayma NOUAJAA; Alena VDOVCHENKO; Karolina AFORS; Hana SALUSSOLIA
- Web page: https://patentgrep.com/patent/US20260097190A1

## CPC

- A61K 9/0036: {Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms}
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 47/02: Inorganic compounds
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61M 2205/0244: Micromachined materials, e.g. made from silicon wafers, microelectromechanical systems [MEMS] or comprising nanotechnology
- A61M 2207/00: Methods of manufacture, assembly or production
- A61M 2210/1475: Vagina
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

A drug delivery device including a porous polymeric material for modulating the delivery of the drug, and a method of manufacture thereof includes: a charged drug delivery device, and a method of manufacture thereof, wherein the charged drug delivery device includes the drug delivery device and a drug, wherein the drug is encapsulated by the drug delivery device, the charged drug delivery device for use in administering a drug, and a kit-of-parts comprising the drug delivery device and a drug for encapsulation in the drug delivery device.

## Claims

### Claim 1

A drug delivery device comprising a porous polymeric material for modulating the delivery of the drug, the porous polymeric material comprising at least one polymer comprising a carbon nanoparticle covalently bonded to a polyurethane moiety.

### Claim 2 (depends on 1)

The drug delivery device according to claim 1, wherein the porogen used for making the pores of the porous polymeric material is a solid material having a particle size of between 65 nm and 1000 μm.

### Claim 3 (depends on 1)

The drug delivery device according to claim 1, wherein the porous polymeric material is coagulated and cured in air at between 5° and 90° C. or in water at between 2 and 90° C.

### Claim 4 (depends on 1)

The drug delivery device according to claim 1, wherein the porogen used for making the pores of the porous polymeric material is present at between 1 and 40 wt. % in the resin precursor used for making it.

### Claim 5 (depends on 1)

The drug delivery device according to claim 1 comprising more than one layer of polymeric material.

### Claim 6 (depends on 1)

The drug delivery device according to claim 1 comprising a wall separating an internal space of the drug delivery device from the outside of the drug delivery device, wherein the internal space is suitable for containing a drug therein and the wall comprises the porous polymeric material.

### Claim 7 (depends on 1)

The drug delivery device according to claim 1, wherein the drug delivery device is a suppository.

### Claim 8 (depends on 1)

The drug delivery device according to claim 1, wherein the drug delivery device is selected from the group consisting of a pessary, tampon, menstrual cup and any other gynaecological device.

### Claim 9

A method of manufacture of a drug delivery device comprising a porous polymeric material for modulating the delivery of the drug, the porous polymeric material comprising at least one polymer comprising a carbon nanoparticle covalently bonded to a polyurethane moiety, wherein the method comprises the following steps:
(i) mixing the porous polymeric material resin precursor with a porogen to form a suspension;
(ii) forming a layer of the suspension; and
(iii) coagulating and curing the layer formed in step (ii).

### Claim 10 (depends on 9)

The method of manufacture according to claim 9, wherein the method comprises additional steps of:
(iv) forming a layer of the suspension on the porous polymeric material;
(v) coagulating and curing the layer formed in step (iv); and
(vi) optionally repeating steps (vi) and (v).

### Claim 11 (depends on 9)

The method of manufacture according to claim 9, wherein the porogen has a particle size of between 65 nm and 1000 μm.

### Claim 12 (depends on 9)

The method of manufacture according to claim 9, wherein the porogen is present at between 1 and 40 wt. % in the resin precursor.

### Claim 13 (depends on 9)

The method of manufacture according to claim 9, wherein coagulating and curing is achieved by exposing the layer formed in step (ii) and/or the laminate formed in step (iv) to air at between 5° and 90° C. or to water at between 2 and 90° C.

### Claim 14 (depends on 1)

A charged drug delivery device comprising:
(a) a drug delivery device according to claim 1; and
(b) a drug, wherein the drug is encapsulated by the porous polymeric material comprised in the drug delivery device.

### Claim 15 (depends on 14)

The charged drug delivery device according to claim 14, wherein the drug is dispersed in a hydrogel matrix encapsulated by the drug delivery device.

### Claim 16 (depends on 1)

A method of manufacture of a charged drug delivery device, wherein the method comprises encapsulating a drug inside the porous polymeric material comprised in the drug delivery device according to claim 1.

### Claim 17 (depends on 16)

The method of manufacture according to claim 16, wherein the drug is dispersed in a hydrogel matrix.

### Claim 18 (depends on 9)

A kit-of-parts comprising:
(a) a drug delivery device comprising a porous polymeric material for modulating the delivery of the drug, the porous polymeric material comprising at least one polymer comprising a carbon nanoparticle covalently bonded to a polyurethane moiety or manufactured according to the method of claim 9; and
(b) a drug for encapsulation in the porous polymeric material comprised in the drug delivery device.

### Claim 19 (depends on 14)

A charged drug delivery device for use in administering a drug, wherein the charged drug delivery device is the charged drug delivery device according to claim 14.
